$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[국내논문] Recent Advances in the Prevention of RSV in Neonates and Young Infants 원문보기

Pediatric infection and vaccine: PIV, v.30 no.1, 2023년, pp.1 - 11  

Ki Wook Yun (Department of Pediatrics, Seoul National University College of Medicine)

초록
AI-Helper 아이콘AI-Helper

Respiratory syncytial virus (RSV)는 전 세계적으로 영유아에게 질병 부담과 사회적 비용이 매우 높은 병원체이지만 그 백신 개발은 상당히 지연되고 있다. 현재로선 단기-지속형 단클론항체인 palivizumab이 유일한 예방법이다. 그러나 최근 RSV 감염의 병태생리학에 대한 이해, 유전학의 발전, 모체 예방접종의 성공적인 시행 등으로 RSV 예방을 위한 단일클론 항체 및 백신의 개발이 급속히 추진되고 있다. 현재 2개의 장기-지속형 단클론항체 제제(nirsevimab 및 clesrovimab)와 2개의 모체 RSV pre-F 백신이 임상 3상 시험을 진행 중이거나 막 완료하였으며, 지금까지의 결과는 효과와 안전성 측면에서 매우 긍정적이다. 가까운 장래에 장기-지속형 단클론항체와 모체 예방접종을 통해 고위험군은 물론이고 기저질환이 없는 신생아 및 영유아들을 RSV로부터 효과적으로 보호할 수 있을 것으로 기대한다. RSV 예방의 새로운 시대에 빠르고 적절히 대비하기 위해서는 이러한 새로운 전략들에 익숙해지고 국내 RSV에 대한 역학 자료들을 계속 수집해 나갈 필요가 있다.

Abstract ▼ AI-Helper 아이콘AI-Helper

Respiratory syncytial virus (RSV) is a pathogen with a high burden of disease and social cost among infants worldwide, but the development of a vaccine has been delayed. The recent understanding of the pathogenesis of RSV, progress in reverse genetics, and successful implementation of other maternal...

Keyword

#Respiratory syncytial virus   #Monoclonal antibody   #Vaccine   #Infant  

참고문헌 (48)

  1. Shi T, McAllister DA, O'Brien KL, Simoes EA, Madhi SA, Gessner BD, et al. Global, regional, and national？disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young？children in 2015: a systematic review and modelling study. Lancet 2017;390:946-58. 

  2. Mejias A, Rodriguez-Fernandez R, Oliva S, Peeples ME, Ramilo O. The journey to a respiratory syncytial？virus vaccine. Ann Allergy Asthma Immunol 2020;125:36-46. 

    상세보기

  3. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, et al. Neutralizing antibodies against？the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical？intervention. Proc Natl Acad Sci U S A 2012;109:3089-94. 

    상세보기

  4. Flynn JA, Durr E, Swoyer R, Cejas PJ, Horton MS, Galli JD, et al. Stability characterization of a vaccine？antigen based on the respiratory syncytial virus fusion glycoprotein. PLoS One 2016;11:e0164789. 

    상세보기

  5. PATH. RSV vaccine and mAb snapshot [Internet]. Addis Ababa: PATH; 2023 [cited 2022 May 4]. Available？from: https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/. 

  6. Simoes EA. The burden of respiratory syncytial virus lower respiratory tract disease in infants in the？United States: a synthesis. J Infect Dis 2022;226 Suppl 2:S143-7. 

  7. Thomas E, Mattila JM, Lehtinen P, Vuorinen T, Waris M, Heikkinen T. Burden of respiratory syncytial？virus infection during the first year of life. J Infect Dis 2021;223:811-7. 

    상세보기

  8. Kang JM, Lee J, Kim YK, Cho HK, Park SE, Kim KH, et al. Pediatric intensive care unit admission due to？respiratory syncytial virus: Retrospective multicenter study. Pediatr Int 2019;61:688-96. 

  9. Yun KW, Choi EH, Lee HJ. Molecular epidemiology of respiratory syncytial virus for 28 consecutive？seasons (1990-2018) and genetic variability of the duplication region in the G gene of genotypes ON1 and？BA in South Korea. Arch Virol 2020;165:1069-77. 

    상세보기

  10. Kim YK, Song SH, Ahn B, Lee JK, Choi JH, Choi SH, et al. Shift in clinical epidemiology of human？parainfluenza virus type 3 and respiratory syncytial virus B infections in Korean children before and？during the COVID-19 pandemic: a multicenter retrospective study. J Korean Med Sci 2022;37:e215. 

  11. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal？antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics？1998;102:531-7. 

    상세보기

  12. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis？reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically？significant congenital heart disease. J Pediatr 2003;143:532-40. 

  13. Lee JH, Kim CS, Chang YS, Choi JH; Committee on Data Collection and Statistical Analysis of the Korean？Society of Neonatology. Respiratory syncytial virus related readmission in preterm infants less than？34 weeks' gestation following discharge from a neonatal intensive care unit in Korea. J Korean Med Sci？2015;30 Suppl 1:S104-10. 

  14. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody？for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev？2013:CD006602. 

  15. Paes BA, Saleem M, Li A, Lanctot KL, Mitchell I; CARESS Investigators. Caress investigators. Respiratory？syncytial virus prophylaxis in immunocompromised children: outcomes from the Canadian RSV evaluation？study of palivizumab registry over twelve seasons (2005-2017). Pediatr Infect Dis J 2020;39:539-45. 

    상세보기

  16. Wang DY, Saleem M, Paes BA, Mitchell I, Li A, Lanctot KL, et al. Respiratory syncytial virus prophylaxis？in neurologic and muscular disorders in the Canadian respiratory syncytial virus evaluation study of？palivizumab. Pediatr Infect Dis J 2019;38:775-80. 

    상세보기

  17. Kim SY, Lee KE, Kang SY, Choi EH, Lee HJ. Evaluation of timeliness of palivizumab immunoprophylaxis？based on the epidemic period of respiratory syncytial virus: 22 year experience in a single center. Pediatr？Infect Vaccine 2015;22:172-7. 

  18. Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, et al. A highly potent extended？half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 2017;9:eaaj1928. 

    상세보기

  19. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for？prevention of RSV in preterm infants. N Engl J Med 2020;383:415-25. 

    상세보기

  20. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of？RSV in healthy late-preterm and term infants. N Engl J Med 2022;386:837-46. 

    상세보기

  21. Domachowske J, Madhi SA, Simoes EA, Atanasova V, Cabanas F, Furuno K, et al. Safety of nirsevimab for？RSV in infants with heart or lung disease or prematurity. N Engl J Med 2022;386:892-4. 

    상세보기

  22. Tang A, Chen Z, Cox KS, Su HP, Callahan C, Fridman A, et al. A potent broadly neutralizing human RSV？antibody targets conserved site IV of the fusion glycoprotein. Nat Commun 2019;10:4153. 

    상세보기

  23. Simoes EA, Forleo-Neto E, Geba GP, Kamal M, Yang F, Cicirello H, et al. Suptavumab for the？prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin Infect Dis？2021;73:e4400-8. 

  24. Langedijk AC, Harding ER, Konya B, Vrancken B, Lebbink RJ, Evers A, et al. A systematic review on global？RSV genetic data: Identification of knowledge gaps. Rev Med Virol 2022;32:e2284. 

    상세보기

  25. Zhu Q, Lu B, McTamney P, Palaszynski S, Diallo S, Ren K, et al. Prevalence and significance of？substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from？antibody MEDI8897. J Infect Dis 2018;218:572-80. 

    상세보기

  26. Oliveira DB, Iwane MK, Prill MM, Weinberg GA, Williams JV, Griffin MR, et al. Molecular？characterization of respiratory syncytial viruses infecting children reported to have received palivizumab？immunoprophylaxis. J Clin Virol 2015;65:26-31. 

    상세보기

  27. Choi SH, Park KS, Kim YJ. Analysis of respiratory syncytial virus fusion protein from clinical isolates of？Korean children in palivizumab era, 2009-2015. J Infect Chemother 2019;25:514-9. 

  28. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus？disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol？1969;89:422-34. 

  29. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered？clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an？inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-21. 

    상세보기

  30. Albrecht M, Arck PC. Vertically transferred immunity in neonates: mothers, mechanisms and mediators.？Front Immunol 2020;11:555. 

  31. Buchwald AG, Graham BS, Traore A, Haidara FC, Chen M, Morabito K, et al. Respiratory syncytial virus？(RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months？of life. Clin Infect Dis 2021;73:e4421-7. 

    상세보기

  32. Roca A, Abacassamo F, Loscertales MP, Quinto L, Gomez-Olive X, Fenwick F, et al. Prevalence of？respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J Med Virol？2002;67:616-23. 

  33. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified？fusion protein-2 vaccine in pregnant women. Vaccine 2003;21:3465-7. 

    상세보기

  34. Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, et al. Respiratory Syncytial Virus？(RSV)-specific antibodies in pregnant women and subsequent risk of RSV hospitalization in young？infants. J Infect Dis 2022;225:1189-96. 

  35. Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, et al. A randomized, blinded, controlled,？dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy？women of childbearing age. J Infect Dis 2016;213:411-22. 

    상세보기

  36. Munoz FM, Swamy GK, Hickman SP, Agrawal S, Piedra PA, Glenn GM, et al. Safety and immunogenicity？of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant？women and their infants. J Infect Dis 2019;220:1802-15. 

    상세보기

  37. Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simoes EA, et al. Respiratory syncytial virus？vaccination during pregnancy and effects in infants. N Engl J Med 2020;383:426-39. 

  38. Beran J, Lickliter JD, Schwarz TF, Johnson C, Chu L, Domachowske JB, et al. Safety and immunogenicity？of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results？from 2 phase 2 trials. J Infect Dis 2018;217:1616-25. 

    상세보기

  39. Schwarz TF, McPhee RA, Launay O, Leroux-Roels G, Talli J, Picciolato M, et al. Immunogenicity and？safety of 3 formulations of a respiratory syncytial virus candidate vaccine in nonpregnant women: a phase？2, randomized trial. J Infect Dis 2019;220:1816-25. 

    상세보기

  40. Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU, et al. A randomized phase 1/2 study of？a respiratory syncytial virus prefusion F vaccine. J Infect Dis 2022;225:1357-66. 

    상세보기

  41. Simoes EA, Center KJ, Tita AT, Swanson KA, Radley D, Houghton J, et al. Prefusion F protein-based？respiratory syncytial virus immunization in pregnancy. N Engl J Med 2022;386:1615-26. 

    상세보기

  42. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, et al. The absence of enhanced？disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated,？respiratory syncytial virus vaccines. Vaccine 2007;25:7372-8. 

    상세보기

  43. Buchholz UJ, Cunningham CK, Muresan P, Gnanashanmugam D, Sato P, Siberry GK, et al. Live？respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity？mutations is highly attenuated in RSV-seronegative infants and children. J Infect Dis 2018;217:1338-46. 

    상세보기

  44. McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentine ME, Perlowski C, et al. Live-attenuated？respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is？highly immunogenic in children. J Infect Dis 2018;217:1347-55. 

    상세보기

  45. McFarland EJ, Karron RA, Muresan P, Cunningham CK, Libous J, Perlowski C, et al. Live respiratory？syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a？promising vaccine candidate in children. J Infect Dis 2020;221:534-43. 

    상세보기

  46. Williams K, Bastian AR, Feldman RA, Omoruyi E, de Paepe E, Hendriks J, et al. Phase 1 safety and？immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding？prefusion F (Ad26.RSV.preF) in adults aged ≥60 years. J Infect Dis 2020;222:979-88. 

    상세보기

  47. Sadoff J, De Paepe E, DeVincenzo J, Gymnopoulou E, Menten J, Murray B, et al. Prevention of respiratory？syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human？challenge study. J Infect Dis 2022;226:396-406. 

    상세보기

  48. Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA, Cao X, et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein？vaccine in healthy younger and older adults. Hum Vaccin Immunother 2021;17:1248-61. 

    상세보기

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로